CAS: 163252-36-6; 1-((2S,3R,4S,5S)-3-Fluoro-4-Hydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)-5-Methylpyrimidine-2,4(1H,3H)-Dione

相似化合物

69256-17-3 784-71-4 69123-94-0

上下游产品

1-[(2R,3R,4R,5R)-3-Fluoro-4-(tetrahydro-pyran-2-yloxy)-5-(tetrahydro-pyran-2-yloxymethyl)-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione O-2,2'-cyclo-5-methyluridine 1-(3,5-O-di(tetrahydropyran-2-yl)-β-D-arabinofuranosyl)thymine 5-Methyluridine10H11FN2O6C10H11FN2O6 5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxy-5-methyluridine 1-(2-deoxy-2-fluoro-3-O-(methylsulfonyl)-5-O-trityl-β-D-arabinofuranosyl)thymine 1-(2-deoxy-2-fluoro-3-O-mesyl-5-O-triphenylmethyl-β-D-arabinofuranosyl)thymine

L-Ribose置于吡啶,盐酸,硫酸氢铵,磺酰氯,硫酸,氨,水,氢溴酸,溶剂黄146,Triethylamine Tris(Hydrogen Fluoride),三乙胺,乙酰氯,六甲基二硅氮烷体系中,用 甲醇,二氯甲烷 用作溶剂,化学反应 162.0H,反应生成克拉夫定
参考文献:A Practical Synthesis Of L-Fmau From L-Arabinose
标题:A Practical Synthesis Of L-Fmau From L-Arabinose
摘要:A Practical Synthesis Of 2'-Deoxy-2'-Fluoro-5-Methyl-Beta-L-Arabinofuranosyl Uracil (14,L-Fmau) Was Developed From L-Arabinose. L-Arabinose Was Converted To L-Ribose 5,Which Was Used For The Synthesis Of Bromosugar 12 Via 2,3,5-O-Tribenzoyl-1-O-Acetyl-Beta-L-Ribofuranose 8,Which Was Subjected To Condensation With Silylated Thymine And The Resulting Protected L-Fmau 13 Was Deprotected To Afford L-Fmau In 14 Steps In 8 % Overall Yield.
Doi:10.1080/15257779908043066

专利信息

专利号:WO-2022256490-A9
优先权日:2021-06-03
标题:Improved synthesis of phosphoramidates for the treatment of hepatitis b virus
发明人：LOCKWOOD MARK
权利人:ANTIOS THERAPEUTICS INC
摘要:The synthesis of phosphoramidate prodrugs useful in the treatment of viral infections is disclosed. Specifically, an improved synthesis of phosphoramidate nucleotides useful in the treatment of Hepatitis B virus is disclosed.

专利号:US-11858953-B2
优先权日:2018-04-04
标 题:Compositions and methods for synthesis of phosphorylated molecules
发明人：CHAPUT JOHN; LIAO JEN-YU; BALA SAIKAT
权利人:UNIV CALIFORNIA
摘要:The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

专利号:US-9334273-B1
优先权日:2014-03-05
标题:Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA)
发明人：CHU DAVID C K; SINGH UMA S
权利人:UNIV GEORGIA
摘要:The invention provides a new convergent approach for the synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) from a readily available starting material (Vince lactam) in fourteen steps. An efficient and practical methodology for stereospecific preparation of a versatile carbocyclic key intermediate, D -2′-fluoro-6′-methylene cyclopentanol by diazotization, elimination, stereoselective epoxidation, fluorination and oxidative reduction of the Vince lactam in twelve steps is also provided.

专利号:US-7125983-B2
优先权日:2000-11-29
标题:L-nucleic acid derivatives and process for the synthesis thereof
发明人：IIZUKA HAJIME; TOGASHI KAZUHIKO; SUZUKI TSUNEJI
权利人:MITSUI CHEMICALS INC
摘要:A novel method has been found to produce 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine. A novel method has been further found to L-2′-deoxyribose derivatives as a useful synthetic intermediate through L-2,2′-anhydro-5,6-dihydrocyclouridine derivative. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now.

专利号:EP-1543168-B1
优先权日:2002-09-27
标 题:Method for assaying replication of hbv and testing susceptibility to drugs
发明人：DURANTEL DAVID; DURANTEL SANDRA; TREPO CHRISTIAN; ZOULIM FABIEN
权利人:INST NAT SANTE RECH MED
摘要:Measuring the replication capacity of hepatitis B virus (HBV), e.g. HBV in a biological sample, possibly in the presence of a pharmaceutical product, and particularly an antiviral agent, is new. Measuring the replication capacity of hepatitis B virus (HBV), e.g. HBV present in a biological sample, possibly in the presence of a pharmaceutical product, particularly an antiviral agent, comprises: (a) optional extraction of nucleic acids contained in the sample; (b) PCR amplification of HBV nucleic acids using at least 2 primer pairs to obtain at least 2 amplified HBV genomic fragments representing more-than-full-length HBV genome; (c) cloning the fragments obtained into a vector; (d) transfecting or transducing susceptible cells with the vector; (e) culturing the transfected or transduced cells in conditions allowing synthesis of HBV pregenomic RNA (pgRNA) from the cloned HBV DNA; (f) optionally treating the cultured cells with a pharmaceutical product, particularly an antiviral agent; and (g) determining the replication capacity of the HBV, and the effect of any pharmaceutical product used on viral gene expression and/or viral replication. Independent claims are also included for: (1) a polynucleotide useful as primer for HBV amplification, comprising a sequence selected from 21 sequences of 23-42 bp (SEQ ID NO: 1-21) given in the specification; (2) a primer pair for HBV amplification comprising: (a) a forward primer comprising SEQ ID NO: 1-12, and/or a reverse primer comprising SEQ ID NO: 13 or SEQ ID NO: 14; (b) a forward primer comprising SEQ ID NO: 15 and/or 16 or 19, and a reverse primer comprising SEQ ID NO: 17 and/or SEQ ID NO: 18; (c) a forward primer comprising SEQ ID NO: 19, and a reverse primer comprising SEQ ID NO: 17 and/or SEQ ID NO: 18; or (d) a forward primer comprising SEQ ID NO: 20 or 22, and a reverse primer comprising SEQ ID NO: 21 or 23; (3) kits for HBV amplification, comprising a primer pair of (2); (4) a vector comprising a more-than-full length HBV genome as defined above, and a promoter modified in the 5' by the presence of a restriction site in the 5' of the +1 of transcription, where the +1 of transcription of the more-than-full length HBV genome and of the promoter are fused, and the promoter controls the synthesis of a pgRNA from the more-than-full length HBV genome post-cell-transfection; and (5) a baculovirus or cell line comprising the vector. ACTIVITY : Virucide. MECHANISM OF ACTION : None given.

专利号:US-11649285-B2
优先权日:2016-08-03
标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
发明人：KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
权利人:BIO TECHNE CORP
摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.